Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People with a performance status rated 0 to 2 (meaning able to carry out daily activities, with at most some limitations) (confirm with trial site)
- Women who have been diagnosed with breast cancer that is localised or locally advanced (has not spread to other parts of the body), of any tumour type
- People whose treatment plan includes 3 to 4 cycles of the chemotherapy drug paclitaxel, possibly combined with other medicines such as trastuzumab, pertuzumab, carboplatin, or endoxan, given either before or after surgery
- People with mild or no nerve damage (peripheral neuropathy grade 1 or less) in both arms, affecting both sides equally, at the time of joining
- People who have detectable pulse in both wrists
- People who have detectable pulses at the ankle or a normal ankle blood pressure reading (confirm with trial site)
- People who have read and signed the informed consent form
- People who are covered by social security (in France)
Who may not be able to join:
- People under 18 years of age
- People diagnosed with breast cancer that has spread to both breasts or to other parts of the body (metastatic or bilateral breast cancer)
- People who have any cancer that has spread to other parts of the body
- People who have moderate to severe nerve damage (peripheral neuropathy grade 2 or higher) in the arms or legs
- People who have nerve damage in their arms that is worse on one side than the other (asymmetric, grade greater than 1)
- People with underlying health conditions that could cause nerve damage, such as diabetes, chronic heavy alcohol use, swelling in one limb (unilateral lymphoedema), or nerve pain following shingles (postherpetic neuralgia), or other conditions at the treating doctor's judgement
- People diagnosed with Raynaud's syndrome (a condition affecting blood flow to the fingers and toes)
- People with blocked arteries in the legs (obstructive arterial disease)
- People with a history of heart attack
- People who are already using compression foot socks
- Pregnant or breastfeeding women
- People who are legally unable to give informed consent, or who have not done so
- Adults who are under a legal protection measure or who are unable to express their consent
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To compare the efficacy in preventing peripheral neuropathy as determined by medical staff between cryotherapy treatment alone and combined cryotherapy and compression treatment of the upper limbs in patients treated with paclitaxel.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.